BACKGROUND: Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children's Cancer Group and Children's Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotype-phenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis). PROCEDURE: To distinguish prognostic subgroups in the genotype-phenotype discordant pNTs, two subgroups, "conventional" and "bull's eye," were identified based on the nuclear morphology. The "conventional" tumors (35 cases) included: Neuroblastoma, poorly differentiated subtype (NB-PD, 26 cases) with "salt-and-pepper" nuclei; neuroblastoma, differentiating subtype (4 cases); ganglioneuroblastoma, intermixed (3 cases); and ganglioneuroma, maturing subtype (2 cases). The "bull's eye" tumors included NB-PD with prominent nucleoli (16 cases). Clinicopathologic characteristics of these two subgroups were analyzed. N-myc protein expression was tested immunohistochemically on available tumors. RESULTS: No significant difference was found between these two subgroups in the distribution of prognostic factors such as age at diagnosis, clinical stage, histopathology category/subtype, mitosis-karyorrhexis index, ploidy, 1p LOH, and unbalanced 11q LOH. However, prognosis of the patients with "conventional" tumors (5-year EFS 85.7 ± 12.2%; OS 89.3 ± 10.3%) was significantly better than those with "bull's eye" tumors (EFS 31.3 ± 13.0%; OS 42.9 ± 16.2%; P = 0.0010 and 0.0008, respectively). Immunohistochemically all (11/11) tested "conventional" tumors were negative, and 10/11 tested "bull's eye" tumors were positive for N-myc protein expression. CONCLUSIONS: Based on the presence or absence of prominent nucleoli (the putative site of RNA synthesis/accumulation leading to N-myc protein expression), two prognostic subgroups, "conventional" with a better prognosis and "bull's eye" with a poor prognosis, were distinguished among the genotype-phenotype discordant pNTs.
BACKGROUND: Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children's Cancer Group and Children's Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotype-phenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis). PROCEDURE: To distinguish prognostic subgroups in the genotype-phenotype discordant pNTs, two subgroups, "conventional" and "bull's eye," were identified based on the nuclear morphology. The "conventional" tumors (35 cases) included: Neuroblastoma, poorly differentiated subtype (NB-PD, 26 cases) with "salt-and-pepper" nuclei; neuroblastoma, differentiating subtype (4 cases); ganglioneuroblastoma, intermixed (3 cases); and ganglioneuroma, maturing subtype (2 cases). The "bull's eye" tumors included NB-PD with prominent nucleoli (16 cases). Clinicopathologic characteristics of these two subgroups were analyzed. N-myc protein expression was tested immunohistochemically on available tumors. RESULTS: No significant difference was found between these two subgroups in the distribution of prognostic factors such as age at diagnosis, clinical stage, histopathology category/subtype, mitosis-karyorrhexis index, ploidy, 1p LOH, and unbalanced 11q LOH. However, prognosis of the patients with "conventional" tumors (5-year EFS 85.7 ± 12.2%; OS 89.3 ± 10.3%) was significantly better than those with "bull's eye" tumors (EFS 31.3 ± 13.0%; OS 42.9 ± 16.2%; P = 0.0010 and 0.0008, respectively). Immunohistochemically all (11/11) tested "conventional" tumors were negative, and 10/11 tested "bull's eye" tumors were positive for N-myc protein expression. CONCLUSIONS: Based on the presence or absence of prominent nucleoli (the putative site of RNA synthesis/accumulation leading to N-myc protein expression), two prognostic subgroups, "conventional" with a better prognosis and "bull's eye" with a poor prognosis, were distinguished among the genotype-phenotype discordant pNTs.
Authors: C S Alvarado; W B London; A T Look; G M Brodeur; D H Altmiller; P S Thorner; V V Joshi; S T Rowe; M B Nash; E I Smith; R P Castleberry; S L Cohn Journal: J Pediatr Hematol Oncol Date: 2000 May-Jun Impact factor: 1.289
Authors: Tamás Tornóczky; Endre Kálmán; Pál G Kajtár; Tibor Nyári; Andrew D J Pearson; Deborah A Tweddle; Julian Board; Hiroyuki Shimada Journal: Cancer Date: 2004-01-15 Impact factor: 6.860
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Larry L Wang; Rie Suganuma; Naohiko Ikegaki; Xao Tang; Arlene Naranjo; Patrick McGrady; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Hiroyuki Shimada Journal: Cancer Date: 2013-07-30 Impact factor: 6.860
Authors: Risa Teshiba; Shinya Kawano; Larry L Wang; Lejian He; Arlene Naranjo; Wendy B London; Robert C Seeger; Julie M Gastier-Foster; A Thomas Look; Michael D Hogarty; Susan L Cohn; John M Maris; Julie R Park; Hiroyuki Shimada Journal: Pediatr Dev Pathol Date: 2014-09-10
Authors: Asuka Kawano; Florette K Hazard; Bill Chiu; Arlene Naranjo; Brian LaBarre; Wendy B London; Michael D Hogarty; Susan L Cohn; John M Maris; Julie R Park; Julie M Gastier-Foster; Naohiko Ikegaki; Hiroyuki Shimada Journal: Am J Surg Pathol Date: 2021-08-01 Impact factor: 6.298
Authors: L L Wang; R Teshiba; N Ikegaki; X X Tang; A Naranjo; W B London; M D Hogarty; J M Gastier-Foster; A T Look; J R Park; J M Maris; S L Cohn; R C Seeger; S Asgharzadeh; H Shimada Journal: Br J Cancer Date: 2015-06-02 Impact factor: 7.640
Authors: Risa Niemas-Teshiba; Ryosuke Matsuno; Larry L Wang; Xao X Tang; Bill Chiu; Jasmine Zeki; Jeannine Coburn; Kimberly Ornell; Arlene Naranjo; Collin Van Ryn; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Shahab Asgharzadeh; Naohiko Ikegaki; Hiroyuki Shimada Journal: Oncotarget Date: 2017-12-15